Overexpression of SRF in hepatocellular carcinoma and breast cancer accelerates cell migration and invasion, and there is a subsequent acquisition of mesenchymal phenotypes due to the expression of a mesenchymal marker (vimentin) (5,10). Here, SRF is linked to breast cancer.